EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

The future of tumor organoids in precision therapy

Seok-Young Kim, Marc van de Wetering, Hans Clevers, Karin Sanders

Trends in Cancer · 2025-07 · 11 (7) · 665-675

DOI: 10.1016/j.trecan.2025.03.005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2025-07. Verfasst von Seok-Young Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Organoids, Precision Medicine, Neoplasms. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Children Cancer Free Foundation, Koninklijke Nederlandse Akademie van Wetenschappen, Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumoroids are cultures of patient-derived tumor cells, which are grown in 3D in the presence of an extracellular matrix extract and specific growth factors. Tumoroids can be generated from adult as well as pediatric cancers, including epithelial cancers, sarcomas, and brain cancers. Tumoroids retain multi-omic characteristics of their corresponding tumor and recapitulate interpatient and intratumor heterogeneity. Retrospective and prospective studies have demonstrated that tumoroids predict patient responses to anticancer therapies, making them a promising tool for precision oncology. However, several challenges remain before tumoroids can be fully integrated into clinical decision-making, including success rates of tumoroid establishment and turnaround times. This review discusses the current advances, challenges, and future directions of tumoroid-based models in cancer research and precision therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OrganoidsPrecision MedicineNeoplasmsHumansAntineoplastic AgentsAnimals

Stichwörter der Autor:innen

cancer organoidpersonalized cancer treatmenttumoroid

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands; Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University Medical Center, Utrecht, The Netherlands; Current address: Roche…
  • Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Electronic address: k.sanders@prinsesmaximacentrum.nl.

Förderung

  • Children Cancer Free Foundation
  • Koninklijke Nederlandse Akademie van Wetenschappen
  • Roche

Zitieren

APA

Kim, S. Y., van de Wetering, M., Clevers, H., & Sanders, K. (2025). The future of tumor organoids in precision therapy. Trends in Cancer, 11(7), 665-675. https://doi.org/10.1016/j.trecan.2025.03.005

Vancouver

Kim SY, van de Wetering M, Clevers H, Sanders K. The future of tumor organoids in precision therapy. Trends in Cancer. 2025;11(7):665-675. doi:10.1016/j.trecan.2025.03.005

BibTeX
@article{Kim2025,
  author = {Kim, Seok-Young and van de Wetering, Marc and Clevers, Hans and Sanders, Karin},
  title = {The future of tumor organoids in precision therapy},
  journal = {Trends in Cancer},
  year = {2025},
  volume = {11},
  number = {7},
  pages = {665--675},
  doi = {10.1016/j.trecan.2025.03.005}
}
Kostenlos starten →